#Veracyte
Investigation Launched Into Veracyte as Shareholders Face Major Losses#USA#New_York#Levi_&_Korsinsky#Veracyte#VCYT
Investigation Launched Into Veracyte as Shareholders Face Major Losses
Levi & Korsinsky announces an investigation into Veracyte due to significant shareholder losses after disappointing test volume results.
third-news.com
November 6, 2026 at 12:52 AM
Recent Stock Decline Sparks Investigation into Veracyte's Securities Practices#USA#New_York#Securities#stock_decline#Veracyte
Recent Stock Decline Sparks Investigation into Veracyte's Securities Practices
Veracyte shares have dropped significantly following disappointing earnings. An investigation into potential securities law violations is underway, impacting investors.
third-news.com
November 6, 2026 at 3:28 PM
Veracyte falls -54.1%
Reported Thursday, Nov 5 - 12:00pm EST (TheFly subscription required to read more.)
thefly.com
November 5, 2026 at 5:01 PM
Veracyte falls -57.7%
Reported Thursday, Nov 5 - 10:00am EST (TheFly subscription required to read more.)
thefly.com
November 5, 2026 at 3:01 PM
The company said that Decipher volume growth is normalizing after two years of strong growth fueled by NCCN guideline changes.
Veracyte Stock Plummets as Firm Lowers Annual Decipher Prostate Test Expectations
Veracyte Stock Plummets as Firm Lowers Annual Decipher Prostate Test Expectations
ebx.sh
November 5, 2026 at 6:32 PM
🚨 Premarket Nov 5: earnings drive everything. 🟢 Sezzle +27%, Sunrun +23%, Warby Parker +22% — beats and raised guides. 🔴 Veracyte −31%, MNTN −45%, ThredUp −24% — guidance cuts. Beat-and-raise gets paid; cuts get punished. 🧠 Penny-stock spikes? Noise. @sezzle @sunrun @warbyparker @veracyte @thredup
November 5, 2026 at 1:00 PM
🚨 $VCYT
On November 4, 2026, Veracyte, Inc. issued a press release announcing its financial results for the quarter ended September 30, 2026. The full text of the press release is furnished as Exhibit 99.1 to this report.
SEC Filing: VCYT
Click to view the official SEC document.
www.sec.gov
November 4, 2026 at 9:20 PM
Veracyte's Prosigna recurrence risk assay now reimbursed by Medicare through MolDX. Expands access to genomic risk stratification for early-stage breast cancer patients in the US.
Veracyte wins Medicare coverage for Prosigna breast cancer test
Veracyte's Prosigna ROR test has secured Medicare reimbursement via the MolDX programme, opening access for eligible early-stage breast cancer patients.
thebiotechtimes.com
November 1, 2026 at 8:00 PM
New opportunity: Manager Software Test Automation at Veracyte in USA #TechCareers #Jobs #GlobalJobs

https://quantumstackjobs.zentrianalytics.com/en/jobs/manager-software-test-automation-veracyte
October 28, 2026 at 11:00 PM
🎯 Medical Science Liaison
🏢 Veracyte

Stop refreshing job boards — gigsniper.net does it for you

#RemoteJobs #Hiring #RemoteWork #HealthcareMedical #FullTime
Medical Science Liaison
Veracyte · via Jobicy · Apply now — found by GigSniper
jobicy.com
October 23, 2026 at 6:02 AM
🎯 Manager Software Test Automation
🏢 Veracyte

Instant alerts for jobs like this → gigsniper.net

#RemoteJobs #Hiring #RemoteWork #QATesting #FullTime
Manager Software Test Automation
Veracyte · via Jobicy · Apply now — found by GigSniper
jobicy.com
October 23, 2026 at 3:02 AM
Six Studies to Highlight Veracyte’s Genomic Tests Across Breast, Prostate and Bladder Cancer at ESMO 2026
Veracyte (Nasdaq: VCYT) announced six studies involving its genomic tests will be presented at ESMO 2026, October 23–27 in Madrid.The presentations cover prostate and bladder cancer treatment selection and risk assessment, plus breast cancer health economics. Veracyte said a Decipher Prostate oral presentation will provide the first evidence that the test predicts benefit from adding abiraterone to androgen deprivation therapy for clinically very high-risk, nonmetastatic prostate cancer. A separate late-breaking oral presentation will report a two-year, within-trial economic analysis of Prosigna-guided chemotherapy decisions in the Phase III OPTIMA breast cancer trial. Four posters address additional prostate and bladder cancer research.
www.stocktitan.net
October 19, 2026 at 12:00 PM